287 related articles for article (PubMed ID: 34369908)
1. Brief Report: Vaginal Viral Shedding With Undetectable Plasma HIV Viral Load in Pregnant Women Receiving 2 Different Antiretroviral Regimens: A Randomized Clinical Trial.
Frenkel LM; Morrison RL; Fuller TL; Gouvêa MI; Benamor Teixeira ML; Coombs RW; Shapiro DE; Mirochnick M; Hennessey R; Whitson K; Chakhtoura N; João EC
J Acquir Immune Defic Syndr; 2021 Dec; 88(4):361-365. PubMed ID: 34369908
[TBL] [Abstract][Full Text] [Related]
2. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.
João EC; Morrison RL; Shapiro DE; Chakhtoura N; Gouvèa MIS; de Lourdes B Teixeira M; Fuller TL; Mmbaga BT; Ngocho JS; Njau BN; Violari A; Mathiba R; Essack Z; Pilotto JHS; Moreira LF; Rolon MJ; Cahn P; Prommas S; Cressey TR; Chokephaibulkit K; Werarak P; Laimon L; Hennessy R; Frenkel LM; Anthony P; Best BM; Siberry GK; Mirochnick M
Lancet HIV; 2020 May; 7(5):e322-e331. PubMed ID: 32386720
[TBL] [Abstract][Full Text] [Related]
3. Impact of antiretroviral regimen on viral suppression among pregnant women living with HIV in Brazil.
Pascom ARP; Fonseca FF; Pinho RGG; Perini FB; Pereira G; Avelino-Silva VI
Int J STD AIDS; 2020 Aug; 31(9):903-910. PubMed ID: 32702281
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women.
Cohan D; Natureeba P; Koss CA; Plenty A; Luwedde F; Mwesigwa J; Ades V; Charlebois ED; Gandhi M; Clark TD; Nzarubara B; Achan J; Ruel T; Kamya MR; Havlir DV
AIDS; 2015 Jan; 29(2):183-91. PubMed ID: 25426808
[TBL] [Abstract][Full Text] [Related]
5. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1.
Mandelbrot L; Landreau-Mascaro A; Rekacewicz C; Berrebi A; Bénifla JL; Burgard M; Lachassine E; Barret B; Chaix ML; Bongain A; Ciraru-Vigneron N; Crenn-Hébert C; Delfraissy JF; Rouzioux C; Mayaux MJ; Blanche S;
JAMA; 2001 Apr; 285(16):2083-93. PubMed ID: 11311097
[TBL] [Abstract][Full Text] [Related]
6. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Siegfried N; van der Merwe L; Brocklehurst P; Sint TT
Cochrane Database Syst Rev; 2011 Jul; (7):CD003510. PubMed ID: 21735394
[TBL] [Abstract][Full Text] [Related]
7. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
Sturt AS; Dokubo EK; Sint TT
Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
[TBL] [Abstract][Full Text] [Related]
8. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Volmink J; Siegfried NL; van der Merwe L; Brocklehurst P
Cochrane Database Syst Rev; 2007 Jan; (1):CD003510. PubMed ID: 17253490
[TBL] [Abstract][Full Text] [Related]
9. 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
Malaba TR; Nakatudde I; Kintu K; Colbers A; Chen T; Reynolds H; Read L; Read J; Stemmet LA; Mrubata M; Byrne K; Seden K; Twimukye A; Theunissen H; Hodel EM; Chiong J; Hu NC; Burger D; Wang D; Byamugisha J; Alhassan Y; Bokako S; Waitt C; Taegtmeyer M; Orrell C; Lamorde M; Myer L; Khoo S;
Lancet HIV; 2022 Aug; 9(8):e534-e543. PubMed ID: 35905752
[TBL] [Abstract][Full Text] [Related]
10. Association of maternal antiretroviral use with microcephaly in children who are HIV-exposed but uninfected (SMARTT): a prospective cohort study.
Williams PL; Yildirim C; Chadwick EG; Van Dyke RB; Smith R; Correia KF; DiPerna A; Seage GR; Hazra R; Crowell CS;
Lancet HIV; 2020 Jan; 7(1):e49-e58. PubMed ID: 31740351
[TBL] [Abstract][Full Text] [Related]
11. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.
Kintu K; Malaba TR; Nakibuka J; Papamichael C; Colbers A; Byrne K; Seden K; Hodel EM; Chen T; Twimukye A; Byamugisha J; Reynolds H; Watson V; Burger D; Wang D; Waitt C; Taegtmeyer M; Orrell C; Lamorde M; Myer L; Khoo S;
Lancet HIV; 2020 May; 7(5):e332-e339. PubMed ID: 32386721
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression.
Huang WC; Huang CK; Huang SH; Lin SW; Ou ST; Chen YT; Chen YW; Chang SY; Liu WC; Sun HY; Hung CC
J Microbiol Immunol Infect; 2021 Oct; 54(5):944-951. PubMed ID: 32675042
[TBL] [Abstract][Full Text] [Related]
13. Perinatal Antiretroviral Intensification to Prevent Intrapartum HIV Transmission When Antenatal Antiretroviral Therapy Is Initiated Less Than 8 Weeks Before Delivery.
Lallemant M; Amzal B; Sripan P; Urien S; Cressey TR; Ngo-Giang-Huong N; Klinbuayaem V; Rawangban B; Sabsanong P; Siriwachirachai T; Jarupanich T; Kanjanavikai P; Wanasiri P; Koetsawang S; Jourdain G; Le Coeur S;
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):313-322. PubMed ID: 32205720
[TBL] [Abstract][Full Text] [Related]
14. Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.
De Castro N; Marcy O; Chazallon C; Messou E; Eholié S; N'takpe JB; Bhatt N; Khosa C; Timana Massango I; Laureillard D; Chau GD; Domergue A; Veloso V; Escada R; Wagner Cardoso S; Delaugerre C; Anglaret X; Molina JM; Grinsztejn B;
Lancet Infect Dis; 2021 Jun; 21(6):813-822. PubMed ID: 33667406
[TBL] [Abstract][Full Text] [Related]
15. Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial.
Chung MH; Kiarie JN; Richardson BA; Lehman DA; Overbaugh J; Kinuthia J; Njiri F; John-Stewart GC
Antivir Ther; 2008; 13(6):799-807. PubMed ID: 18839781
[TBL] [Abstract][Full Text] [Related]
16. Resistance to antiretrovirals in HIV-infected pregnant women.
Weinberg A; Forster-Harwood J; McFarland EJ; Pappas J; Davies JK; Kinzie K; Barr EA; Paul SM; Salbenblatt CR; Soda E; Vazquez A; Levin MJ
J Clin Virol; 2009 May; 45(1):39-42. PubMed ID: 19329355
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of Option B+ ART in Malawi: few severe maternal toxicity events or infant HIV infections among pregnant women initiating tenofovir/lamivudine/efavirenz.
Harrington BJ; DiPrete BL; Jumbe AN; Ngongondo M; Limarzi L; Wallie SD; Chagomerana MB; Hosseinipour MC;
Trop Med Int Health; 2019 Oct; 24(10):1221-1228. PubMed ID: 31381233
[TBL] [Abstract][Full Text] [Related]
18. Persistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancy.
Kakehasi FM; Tupinambás U; Cleto S; Aleixo A; Lin E; Melo VH; Aguiar RA; Pinto JA
AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1515-20. PubMed ID: 18160009
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team.
Mofenson LM; Lambert JS; Stiehm ER; Bethel J; Meyer WA; Whitehouse J; Moye J; Reichelderfer P; Harris DR; Fowler MG; Mathieson BJ; Nemo GJ
N Engl J Med; 1999 Aug; 341(6):385-93. PubMed ID: 10432323
[TBL] [Abstract][Full Text] [Related]
20. Pregnancies Among the First Generation of Survivors of Perinatal HIV Infection.
Trahan MJ; Boucher M; Renaud C; Karatzios C; Metras ME; Valois S; Ransy DG; Lamarre V; Kakkar F
J Obstet Gynaecol Can; 2020 Apr; 42(4):446-452. PubMed ID: 31882286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
